GlassScriptPhysician profile
Ronald Midyett
NPI 1013401488
$1,554.01
in general payments reported to CMS, 2019-2025
17 companies · $599 in 2025
The $599 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.91 · 2024: $895 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $326.18 | 2024-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $298.67 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $120.49 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.84 | 2024-2025 | Jardiance |
| Abbott Laboratories | $103.89 | 2024 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $97.97 | 2024-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $92.68 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $76.10 | 2024-2025 | |
| Pfizer INC. | $72.98 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $55.75 | 2023-2024 | |
| Amgen INC. | $46.43 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $45.08 | 2025 | |
| Alnylam Pharmaceuticals INC. | $27.63 | 2024 | Onpattro |
| Novartis Pharmaceuticals Corporation | $26.46 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $20.58 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daxor Corporation | $19.44 | 2024 | Bva-100 |
| Kiniksa Pharmaceuticals International, Plc | $13.84 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Midyett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.